U.S., July 9 -- ClinicalTrials.gov registry received information related to the study (NCT07054190) titled 'A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer' on June 26.
Brief Summary: This study will evaluate the safety and efficacy of inavolisib combination therapies in participants with untreated, PIK3CA-mutated, Stage II-III, estrogen receptor (ER)-positive, Human Epidermal Growth Factor Receptor 2 (HER2)-negative breast cancer (BC).
Study Start Date: July 14
Study Type: INTERVENTIONAL
Condition:
Breast Cancer
Intervention:
DRUG: Inavolisib
Inavolisib will be administered as per the schedule specified in the arms
DRUG: Ribociclib
Ribociclib will be administered as per the sch...